Peritoneal Dialysis
Continuous ambulatory peritoneal dialysis (CAPD) is a therapy used to replace kidney function in end stage renal disease patients, originally described by Popovich et al in 1978 1 . The therapy is based on the ability of the peritoneal membrane to function as a dialysing membrane, allowing exchange of solutes and waste products between the peritoneal dialysis fl uid (PDF) and the circulation.
PDF is instilled in the peritoneal cavity via a permanent catheter. Through this catheter approximately 2 litre of PDF is instilled and drained using gravity as a driving force. The PDF is usually exchanged four times a day with dwell times of 4-6 hours during day time, and a long dwell of 8-10 hours during the night. Alternatively, fl uid exchanges can be performed by an automated procedure at night, with a long dwell during the day (automated peritoneal dialysis, APD).
Transport of solutes between the blood and the peritoneal cavity follows two major principles; diffusion and convention. Diffusive transport through the peritoneal membrane is driven by differences in solute concentration on either side of the membrane and occurs in the direction of the concentration gradient. The removal of solutes by convection occurs with the transport of water across the membrane and is determined by the amount of ultrafi ltration. When there is a net fl uid fi ltration into the peritoneum, excess fl uid and waste products can be removed during peritoneal dialysis (PD). The presence of an osmotic agent in the PDF, mostly glucose, facilitates fl uid movement from the bloodstream to the peritoneal cavity, leading to removal of metabolic waste products and water.
Continuous removal of waste products achieved using PD, results in improved well-being of patients, partly as a result of stabilisation of the amount of waste products in the body. This is in contrast to haemodialysis (HD) where waste products accumulate in-between two dialysis treatments. Patients on PD have increased mobility compared to HD since PD can be done at home. In addition PD is less expensive. Drawbacks of PD include the risk of peritonitis and peritoneal membrane damage upon exposure to PDF. The latter can induce infl ammation and regeneration processes, as well as tissue remodelling, which ultimately can lead to technique failure.
Currently, there are more than 190.000 patients on PD worldwide, representing approximately 10% of the total population of patients with end stage renal disease (ESRD) 2 . In the Netherlands PD is used by ~20% of the Dutch dialysis population, being approximately 1200 out of 6000 patients. It is anticipated that the number of PD patients will increase during the next decade, especially in developing countries 3 .
PD-related tissue remodelling
The effi cacy of PD depends on the structural and functional integrity of the peritoneum, i.e. the inner surface of the abdominal wall (parietal peritoneum) and omentum and mesentery (visceral peritoneum). The peritoneum consists of a mesothelial cell monolayer and underlying connective tissue interstitium comprising extracellular matrix (ECM), blood vessels, lymphatics, fi broblasts and immune cells. To study the integrity of these tissues and to gain more insight into processes in the peritoneal cavity upon instillation with PDF, several animal models for PD have been described 4 .
These animal models can be used to study many aspects of PD, including bio(in) compatibility, new osmotic agents, peritoneal membrane transport physiology and permeability as well as the effects of therapeutic interventions. Animal models of PD differ in the animal species, ways of fl uid instillation, duration of the experiments and in the amount of fl uid injected. However, daily drainage of the effl uent has shown to be hardly possible in all models because of omental outgrowth around the catheter.
Therefore most models are peritoneal exposure models.
In these animal models it has been shown that several weeks of PD results in a loss of mesothelial cells and denuded areas in the mesothelial layer (Figure 1 A,B ) 5 .
Liver imprints of rats show increased mesothelial cell density, indicating mesothelial regeneration (Figure 1 C,D) 6;7 . Among these mesothelial cells, vimentin positive, spindle-shaped cells are found indicating the process of epithelial to mesenchymal transition (EMT) 8 . Morphological changes also take place in the sub-mesothelial interstitium were the ECM thickness is signifi cantly increased upon PD (Figure 1 E,F) [9] [10] [11] . In the parietal peritoneum granulation tissue (immune cell aggregates) is observed within the matrix layer 7 . Signifi cantly higher numbers of immune cells are found in the effl uents of PD-treated animals compared to non-treated animals.
Although the percentage of macrophages and lymphocytes does not change, an exchange of mast cells and eosinophils for neutrophils is seen after PD treatment 10;11 .
Increased numbers of activated macrophages are seen in peritoneal tissues upon PD 8 , including accumulations around vessel networks in the omentum, known as milky spots (Figure1 G,H) 10;12 . Normally, milky spots occupy a small percentage of the total surface area of the omentum, whereas after PDF exposure this increases dramatically 6;13 . In addition, throughout the peritoneal tissues new blood vessels (Figure 1 I,J) 10 and lymphatics are formed. Angiogenesis leads to a large effective surface area exchange whereas lymphangiogenesis will result in increased lymphatic absorption rates 14;15 . Ultrafi ltration loss as a result of (lymph)angiogenesis, is in part caused by a decrease in the glucose-driven osmotic pressure of the PDF due to a larger vascular network. Secondly, angiogenesis induces subtle changes in the thickening of the vessel wall which can lead to the elevation of small solute transport across the peritoneal membrane, and thus contributes to ultrafi ltration loss 14;15 .
The thickened sub-mesothelial fi brotic layer hampers osmotic pressure further, and reduces the effi cacy of the exchanges 9 . In summary, loss of mesothelium, submesothelial fi brosis and (lymph)angiogenesis are typical morphologic features seen in long term PD contributing to technique failure 9;16 . 
Causes of PD-induced peritoneal membrane changes
Several factors can contribute to PD-related tissue remodelling, including uraemia, peritonitis, the presence of the catheter and instillation of the PDF itself. Different components of PDF, including buffer, low pH, glucose concentration and glucose degradation products (GDPs) generated during heat sterilisation, infl uence peritoneal remodelling 17 ( Table 1 Table 1 : Peritoneal changes occurring after long term PD fl uid exposure in rats GDPs = glucose degradation products. Peritoneal changes are indicated from -(no changes), + (moderate) to ++ (strong) and +++ (very strong) compared to control rats.
It has become increasingly clear that more biocompatible PDF (bicarbonate/lactate buffer, low GDPs) induce less damage and less impaired ultrafi ltration 6;11;20;23 . In addition, supplementing PDF with aminoguanidine, which scavenges GDPs and prevents AGE formation, resulted in less mesothelial denudation 24 , fi brosis and angiogenesis in omentum and parietal peritoneum 25 .
Apart from PDF composition, other factors have been suggested to contribute to PDrelated tissue remodelling. In uremic patients, AGEs, vascular endothelial growth factor (VEGF) and infl ammatory cytokines (such as interleukin-1beta (IL-1β) and tumour necrosis factor alpha (TNFα)) are signifi cantly increased and are known to modulate the structure and function of the peritoneal membrane 26 . Studies have shown that uraemia leads to thickening of the ECM and mild vasculopathy, indicating that uraemia induces infl ammation and tissue remodelling in the peritoneum 9;27 .
Animal studies confi rmed the increase in vascular network as a result of uraemia in non-PD treated animals. However, only minor differences between uremic and nonuremic PD treated rats were found, suggesting that there is no prominent effect of uraemia in PD therapy 28;29 .
In contrast, peritonitis episodes signifi cantly contribute to peritoneal changes by inducing mesothelial damage, massive infl ammatory response and increased vascularisation of peritoneal tissue leading to impaired membrane function 14;30;31 .
Cells that contribute to peritoneal tissue remodelling
Peritoneal tissue remodelling resembles a chronic low grade of infl ammation. Major cell types involved include macrophages and mast cells, together with mesothelial cells, fi broblasts and endothelial cells. Figure 2 shows the cellular system known to contribute to PD-induced changes, including the cytokines and chemokines produced. 64 . Exposure of endothelial cells to pro-infl ammatory cytokines, including IL1β and TNFα, induces the production of IL-8, MCP-1, the recruitment of leukocytes to the cell surface, and cell death 65 .
Endothelial cells of the vessels observed in the milky spots of PD treated animals are greatly enlarged, showing their activation 6 . Indeed, rolling, adhesion and extravasation of leukocytes is dramatically increased in newly formed blood vessels in mesenteries of long-term PD treated animals 66;67 . Apart from its role in infl ammation, the endothelium lining peritoneal capillaries is the most important barrier for solute transport during PD. Water transport during PD requires ultrasmall pores in the capillary endothelium and is impaired in the case of peritoneal infl ammation 68 . The water channel aquaporin-1 (AQP-1) has been proposed to be the ultrasmall pore in animal models 68 . Neither uraemia nor PD alters AQP-1 expression within peritoneal capillary endothelium, suggesting that a quantitative loss of ultrasmall pores itself may not be responsible for ultrafi ltration failure 68 .
Cytokines, growth factors and hormones that mediate peritoneal tissue remodelling
Pro-infl ammatory cytokines/chemokines: As mentioned, activated macrophages play a key role in PD-mediated tissue remodelling as one of the main producers of pro-infl ammatory cytokines including IL-1β, IL-6, IL-8, TNFα, and MCP-1 69 .
Over-expression of IL-1β and TNFα in rat peritoneal mesothelial cells by adenovirus gene transfer leads to an acute infl ammatory response and expression of VEGF and TGFβ, resulting in angiogenesis and fi brosis 70 . IL-8 promotes accumulation and activation of neutrophils 69 , whereas MCP-1 recruits mononuclear cells 34 . MCP-1 and IL-8 levels are found in steady state PD effl uents and increase upon peritonitis 31 .
Interestingly, HA fragments induce the release of IL-8 and MCP-1 by mesothelial cells 71 . Mesothelial cells are considered as a source of HA upon infl ammation and wound healing 72 . High molecular weight HA is thought to support healing of the injured mesothelium by creating a fi brin network and limiting damaging effects of free radicals 71 . In PD effl uents, increased levels of HA are found, although it is not clear whether this represents HA fragments, high molecular weight, or both.
Growth factors: Several growth factors contribute to peritoneal tissue remodelling of which VEGF and TGFβ are the most important. VEGF is an endothelial specifi c growth factor, produced in the peritoneum by mesothelial cells. VEGF affects endothelial permeability and contributes to the induction of angiogenesis 73 . Inhibition of VEGF function in rats by anti-VEGF antibodies prevented peritoneal angiogenesis leading to normalized small solute transport rates upon high glucose exposure 74 . It is noteworthy that glucose may exert little effect on VEGF production, whereas GDPs or AGEs greatly enhance VEGF production. TGFβ is strongly up-regulated by high glucose concentrations, inducing peritoneal fi brosis 73 . Overexpression of TGFβ in the peritoneum of rodents caused peritoneal fi brosis, angiogenesis, EMT, increased peritoneal membrane transport and reduced ultrafi ltration 44;75 . On the other hand, inactivation of TGFβ did not affect ultrafi ltration rate or angiogenesis but did reduce fi brosis 76 . Some experimental work is done on platelet-derived growth factor (PDGF) and FGF-2 [77] [78] [79] [80] suggesting that these growth factors might be involved in PD-related tissue remodelling. COX-2 is present at the site of infl ammation and is expressed by macrophages and monocytes. It is induced by IL-1, TNFα, and growth factors 99 . In cancer, COX-2 downstream products (mainly PGE2) mediate angiogenic processes through mechanisms including VEGF production and enhanced endothelial cell survival 100 .
In vitro experiments demonstrated that mesothelial and infl ammatory cells express COX-2 under PD-like conditions 77;101 . Fibroblasts involved in peritoneal healing after abdominal surgery have been found positive for COX-2 expression 102 . In a recent chronic animal PD study, the COX-2 inhibitor Celecoxib improved ultrafi ltration, and largely prevented angiogenesis and fi brosis in peritoneal tissues 103 .
p38 MAPK: The p38 MAPK pathway is strongly activated by environmental stressors including pro-infl ammatory cytokines and osmolality changes. It leads to alterations in cell growth and cellular dysfunction [104] [105] [106] . The p38 MAPK is critical for the production of nuclear factor-kappa B (NF-κB)-dependent infl ammatory cytokines including 
Peritoneal rest and reversibility
Activation of peritoneal cells, mediators and pathways, results in functional and structural changes of peritoneal membranes in long-term PD. Some of these changes can be reversed by peritoneal rest. Peritoneal rest by switching temporarily to haemodialysis can help restore ultrafi ltration 134;135 . Also switching from chronic ambulant PD to daytime ambulatory PD with a nocturnal "empty belly", has been reported to improve ultrafi ltration 136 . Besides these clinical implications, the reversibility of both morphological and functional alterations in the peritoneal membrane by peritoneal rest was shown in animal studies 137;138 .
Peritoneal rest of more than 4 weeks restored ultrafi ltration capacity as well as peritoneal permeability for glucose and total protein 137;138 . Moreover, the thickness of the parietal peritoneum was reduced and omental and mesenterial vessel density was restored 137;138 . Furthermore, peritoneal rest reversed the increased mast cell density and milky spot response and recovered PD-induced mesothelial cell damage 138 .
These data suggest that PD-induced changes in the peritoneal membrane are generally reversible after peritoneal rest, as shown in the rat model.
Aim and outline of thesis
The condition of the peritoneal membrane is crucial to continue CAPD as a renal replacement therapy. In long term PD, uraemia, peritonitis and permanent exposure to PDF induce morphological changes of the peritoneal membranes leading to discontinuation of PD therapy. As described above, these morphological changes are caused by many peritoneal cells, growth factors and pathways which are activated during PD and interrelated to each other.
Therefore the aim of this thesis is to fi nd strategies to prevent these processes and thereby longer preserve the peritoneum for peritoneal dialysis. The understanding of infl ammatory, fi brotic and neo-angiogenic processes during PD and the prevention of these processes can contribute to a prolonged time on PD treatment. Figure 3 shows possibilities for therapeutic interventions on the different levels that To be able to preserve the peritoneal membrane, early detection of peritoneal infl ammation is crucial. We therefore studied leukocyte-endothelium interactions in vivo in our rat PD model, with and without the presence of an infl ammatory stimulus in chapter 7.
To identify new biomarkers we have set up a microarray and proteomics approach to select genes or proteins which can have a predictive value or may be potentially useful as a target for new therapeutic interventions. In chapter 8 we have performed microarray analysis on peritoneal tissues of rats and investigated whether Neutrophil Gelatinase Associated Lipocalin (NGAL) can be used as a marker for mesothelial damage. In chapter 9 we used a proteomics approach to search for new biomarkers in human dialysates.
Finally, in chapter 10, the fi ndings described in this thesis are summarized and discussed. Clinical implications are addressed and future therapeutic strategies are recommended.
